Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

7 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Bioavailability and Pharmacokinetics of Testosterone with/without Dutasteride - 106218 - Part 2 - Repeat Dose Phase Day 25 - Investigational Product/Treatment Confirmation

- 04/03/2019 - 1 Formulaire, 3 Groupes Item, 7 Eléments de données, 1 Langue
Groupes Item: Administrative documentation, Experimental drug, Therapeutic Procedure, Confirmation
Study ID: 106218 Clinical Study ID: TDC106218 Study Title: Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride  Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: testosterone Trade Name: Andropatch,Androderm Study Indication: Hypogonadism, Male

Bioavailability and Pharmacokinetics of Testosterone with/without Dutasteride - 106218 - Part 2 - Repeat Dose Phase Day 24 - Investigational Product/Treatment Confirmation

- 04/03/2019 - 1 Formulaire, 3 Groupes Item, 7 Eléments de données, 1 Langue
Groupes Item: Administrative documentation, Experimental drug, Therapeutic Procedure, Confirmation
Study ID: 106218 Clinical Study ID: TDC106218 Study Title: Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride  Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: testosterone Trade Name: Andropatch,Androderm Study Indication: Hypogonadism, Male

Bioavailability and Pharmacokinetics of Testosterone with/without Dutasteride - 106218 - Part 2 - Repeat Dose Phase Day 26 - Investigational Product/Treatment Confirmation

- 04/03/2019 - 1 Formulaire, 3 Groupes Item, 7 Eléments de données, 1 Langue
Groupes Item: Administrative documentation, Experimental drug, Therapeutic Procedure, Confirmation
Study ID: 106218 Clinical Study ID: TDC106218 Study Title: Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride  Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: testosterone Trade Name: Andropatch,Androderm Study Indication: Hypogonadism, Male

Bioavailability and Pharmacokinetics of Testosterone with/without Dutasteride - 106218 - Part 2 - Treatment Period Day 19 - Investigational Product/Treatment Confirmation

- 04/03/2019 - 1 Formulaire, 3 Groupes Item, 7 Eléments de données, 1 Langue
Groupes Item: Administrative documentation, Experimental drug, Therapeutic Procedure, Confirmation
Study ID: 106218 Clinical Study ID: TDC106218 Study Title: Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride  Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: testosterone Trade Name: Andropatch,Androderm Study Indication: Hypogonadism, Male

Bioavailability and Pharmacokinetics of Testosterone with/without Dutasteride - 106218 - Part 2 - Repeat Dose Phase Day 20 - Investigational Product/Treatment Confirmation

- 04/03/2019 - 1 Formulaire, 3 Groupes Item, 7 Eléments de données, 1 Langue
Groupes Item: Administrative documentation, Experimental drug, Therapeutic Procedure, Confirmation
Study ID: 106218 Clinical Study ID: TDC106218 Study Title: Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride  Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: testosterone Trade Name: Andropatch,Androderm Study Indication: Hypogonadism, Male

GSK Study to Evaluate the Relative Bioequivalence of Two New Small Tablet Formulations of Lapatinib in Healthy Subjects 102587 - Consent for PGx-Pharmacogenetic research

- 22/03/2018 - 1 Formulaire, 1 Groupe Item, 10 Eléments de données, 1 Langue
Groupe Item: Consent for PGx Pharmacogenetic research
Study ID: 102587 Clinical Study ID: EGF102587 Study Title: A Single-Dose, Open-Label, Randomized, Three-Way Cross-Over Study in Healthy Subjects to Evaluate the Relative Bioequivalence of Two New Small Tablet Formulations of Lapatinib (GW572016) Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tykerb,Tycerb,Tyverb; Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Breast Documentation part: Consent for PGx-Pharmacogenetic research

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening

- 30/06/2015 - 1 Formulaire, 6 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Subject details, Demographics, Informed consent, Eligibility criteria, Pre-randomization status, Treatment assignment
Study documentation part: Screening This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial